VERACYTE INC (VCYT)

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 787 full-time employees. The company went IPO on 2013-10-30. The firm is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. The company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. The company also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. The company also offers customized biomarker testing and analytical services.

Company Info

VERACYTE INC

6000 Shoreline Court, Suite 300

South San Francisco CALIFORNIA 94080

P: 16502436300

CEO: Bonnie H. Anderson

Employees: 787

Website: https://www.veracyte.com/